Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.
| Revenue (TTM) | $213.00M |
| Gross Profit (TTM) | $85.08M |
| EBITDA | $-3.74M |
| Operating Margin | -38.60% |
| Return on Equity | -33.10% |
| Return on Assets | -5.71% |
| Revenue/Share (TTM) | $1.45 |
| Book Value | $1.37 |
| Price-to-Book | 5.08 |
| Price-to-Sales (TTM) | 9.17 |
| EV/Revenue | 5.38 |
| EV/EBITDA | 1.77 |
| Quarterly Earnings Growth (YoY) | -32.70% |
| Quarterly Revenue Growth (YoY) | 10.10% |
| Shares Outstanding | $148.99M |
| Float | $106.40M |
| % Insiders | 7.22% |
| % Institutions | 100.18% |
Volatility is currently expanding
Maravai LifeSciences NASDAQ: MRVI raised its 2026 revenue and adjusted EBITDA forecasts after reporting third-quarter sales growth of 10%, driven by demand for mRNA products and continued growth at its Cygnus business.
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $45.9 million, Net loss of $(24.0) million, and Adjusted EBITDA of $5.8 million; Full year 2026 revenue guidance range increased to $212.0 million to $.
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of November. On November 12, 2026, at 10:40 a.m. EST, Raj Asarpota, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York City, NY. On November 17, 2026, at 4:00 p.m.
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter financial and operating results after the market close on Wednesday, November 4, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4849 or 1-203-518-9848 and reference Marav.
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5., named "Compositions and Methods for Synthesizing 5'-Capped RNAs." The patent marks TriLink's second granted CleanCap® patent in China within a matter of months, and expands.
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Maravai LifeSciences NASDAQ: MRVI reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million; Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 milli.
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter financial and operating results after the market close on Thursday, August 6, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-579-2543 or 1-785-424-1789 and reference Maravai.
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules. The new patent covers TriLink's full suite of CleanCap® capping analogs, including its latest M6 analog. CleanCap technology is a critical com.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRVI and any ticker you trade — then tracks every position and per-strategy win rate.
